By JoAnne Foody MD FACC FAHA
New cardiac medications are being constructed at a speedy velocity. a number of new medicinal drugs and sessions of substances are reviewed during this factor, which will help cardiologists hold updated with the most recent drug details.
Read or Download Cardiology Drug Update, An Issue of Cardiology Clinics PDF
Similar cardiovascular books
It is a 3-in-1 reference booklet. It supplies a whole scientific dictionary protecting 1000s of phrases and expressions on the subject of middle failure. It additionally supplies wide lists of bibliographic citations. eventually, it presents details to clients on the right way to replace their wisdom utilizing a number of net assets.
Over the last 20 years, as a result of dramatic advances in molecular and mobilephone biology, biochemistry, and genetics, our view on mitochondria as a comparatively static mobile powerhouse has replaced extensively. We now be aware of that those organelles play a serious position within the basic and within the broken center. Written by way of Dr.
Das Buch bietet kompaktes Wissen – genau zugeschnitten auf die Bedürfnisse des Arztes, der in die Herzschrittmacher-Kontrolle einsteigt. - Algorithmen und Anleitungen zu allen wichtigen Krankheitsbildern- Zahlreiche Abbildungen der verschiedenen Gerätetypen und software program erleichtern die Kontrolle- Übersichtliche Tabellen erleichtern das schnelle Finden der wichtigen Arbeitsschritte- Hochaktuell mit einem eigenen Kapitel zu biventrikulären Schrittmachern- Verfasst von einem erfahrenen Autoren-team, das den Alltag und die Tücken der Herzschrittmacher-Kontrolle bestens kennt.
Landmark Papers in Cardiology presents an in depth precis of an important trials and stories in cardiology, that have lead the way for breakthroughs within the medical administration of the complete spectrum of heart problems. each one bankruptcy is written by way of a well-liked overseas heart specialist in that specific box, making this e-book crucial analyzing for all cardiologists and cardiovascular trainees.
- Échocardiographie pédiatrique et foetale
- Central Adrenaline Neurons. Basic Aspects and Their Role in Cardiovascular Functions
- Mitral valve transesophageal echocardiography
- Cardiovascular Aspects of Dialysis Treatment: The importance of volume control
- Bedside Cardiology
- Clinical Arrhythmology
Additional info for Cardiology Drug Update, An Issue of Cardiology Clinics
J Am Coll Cardiol 2006;48(9):1782–90 [Abstract]. Thuren T, Longcore A, Powell C, et al. Effect of torcetrapib combined with atorvastatin on HDL-C and LDL-C levels, particle size, and composition: a phase 2 dose-ranging clinical trial. Atheroscler Suppl 2006;7(3):550–550. Nissen SE, Tardif J-C, Nicholls SJ, et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007;356(13):1304–16. Diringer K, Gibbs MA, Amin N, et al. Lack of an effect of ezetimibe on the pharmacokinetics of torcetrapib/atorvastatin in healthy subjects.
Brousseau ME, Schaefer EJ, Wolfe ML, et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 2004;350(15): 1505–15. Brousseau ME, Diffenderfer MR, Millar JS, et al. Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion. Arterioscler Thromb Vasc Biol 2005;25(5):1057–64. Davidson MH, McKenney JM, Shear CL, et al. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels.
At the end of 2 years, despite significant rise in HDL-c and reduction in LDL-c levels, there was no difference in the progression of carotid IMT among the intervention and control groups in both RADIANCE 1 and 2. The Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation (ILLUSTRATE) trial studied the effect of torcetrapib on coronary atherosclerosis progression. 63 All patients underwent intravascular ultrasonography (IVUS) at baseline and 77% of them had a repeat IVUS after 2 years.